Sample size determination in reference-controlled diagnostic trials

被引:7
|
作者
Krummenauer, F
Kauczor, HU
机构
[1] Johannes Gutenberg Univ Mainz, Inst Med Biometrie Epidemiol & Informatik, D-55131 Mainz, Germany
[2] Johannes Gutenberg Univ Mainz, Klin & Poliklin Radiol, D-55131 Mainz, Germany
来源
ROFO-FORTSCHRITTE AUF DEM GEBIET DER RONTGENSTRAHLEN UND DER BILDGEBENDEN VERFAHREN | 2002年 / 174卷 / 11期
关键词
diagnostic reference; sensitivity; sample size; confidence intervals;
D O I
10.1055/s-2002-35346
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: A tutorial illustration of a flexible approach to determine the sample size in reference-controlled diagnostic trials. Materials and Methods: Assuming the usual setting of a new diagnostic method to be compared with a reference method, the emphasis is on the sensitivity of the new method in comparison with the reference method, using a binary outcome (positive versus negative) for both methods. Based on the confidence interval of the sensitivity, a simple but flexible procedure for determining the sample size is described, which incorporates clinically interpretable information. The procedure is illustrated by the fictious planning of a trial to assess the diagnostic value of MRI versus arthroscopy as a reference, in the detection of meniscal ruptures. Results: The principal investigator merely has to propose the range for the sensitivity in which the new method is considered equal to the reference method. Furthermore, it must be decided in advance how accurate the study outcome should determine the sensitivity of the new method, i.e., how wide its maximum confidence interval may become. The minimum sample size necessary for the trial can be directly derived from this outlined strategy, which can easily be extended by simultaneous consideration of sensitivity and specificity of the new method being tested. Conclusion: The flexible approach to planning by means of the confidence interval of the sensitivity controls the desired confidence of the outcome of the diagnostic trial. It allows a priori evaluation of study budget, study duration, number of study centers and, above all, any ethical limitations. It provides arguments for the investigator to proceed with the comparison and a rationale for the decision to conduct the comparison as mono- or multicentric trial.
引用
收藏
页码:1438 / 1444
页数:7
相关论文
共 50 条
  • [1] Sample size recalculation in sequential diagnostic trials
    Tang, Liansheng Larry
    Liu, Aiyi
    BIOSTATISTICS, 2010, 11 (01) : 151 - 163
  • [2] Sample-size determination and adherence in randomised controlled trials published in anaesthetic journals
    Nontshe, M.
    Khan, S.
    Mandebvu, T.
    Merrifield, B.
    Rodseth, R. N.
    SOUTHERN AFRICAN JOURNAL OF ANAESTHESIA AND ANALGESIA, 2018, 24 (02) : 40 - 46
  • [3] Sample size estimation for cluster randomized controlled trials
    Ribeiro, Daniel Cury
    Milosavljevic, Stephan
    Abbott, J. Haxby
    MUSCULOSKELETAL SCIENCE AND PRACTICE, 2018, 34 : 108 - 111
  • [4] Sample Size Determination for Cost-Effectiveness Trials
    Willan, Andrew R.
    PHARMACOECONOMICS, 2011, 29 (11) : 933 - 949
  • [5] Methods for sample size determination in cluster randomized trials
    Rutterford, Clare
    Copas, Andrew
    Eldridge, Sandra
    INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2015, 44 (03) : 1051 - 1067
  • [6] Bayesian sample size determination for diagnostic accuracy studies
    Wilson, Kevin J.
    Williamson, S. Faye
    Allen, A. Joy
    Williams, Cameron J.
    Hellyer, Thomas P.
    Lendrem, B. Clare
    STATISTICS IN MEDICINE, 2022, 41 (15) : 2908 - 2922
  • [7] Sample size estimation in diagnostic test studies of biomedical informatics
    Hajian-Tilaki, Karimollah
    JOURNAL OF BIOMEDICAL INFORMATICS, 2014, 48 : 193 - 204
  • [8] A Bayesian decision approach for sample size determination in phase II trials
    Leung, DHY
    Wang, YG
    BIOMETRICS, 2001, 57 (01) : 309 - 312
  • [9] Bayes Models of Clinical Trials with Dichotomous Outcomes and Sample Size Determination
    Zaslavsky, Boris G.
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2009, 1 (02): : 149 - 158
  • [10] Sample size determination for clinical trials in patients with nonlinear disease progression
    Yan, X
    Su, XG
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2006, 16 (01) : 91 - 105